Clinical trials: Primary IgA Nephropathy
Primary IgA Nephropathy
The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.
MIMIGA Study Title: Modification of Intestinal Microbiome in Patients with Primary IgA Nephropathy (IgAN) Objective: To evaluate whether supplementation with short-chain fatty acids (SCFAs)-specifically sodium butyrate-can reduce…
- Trial name
- MIMIGA (NCT07750249)
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- University Hospital, Martin
Primary IgA Nephropathy
Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy
NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade.
- Trial name
- NCT06982040
- Testing
- NTQ5082 capsules 100 mg, NTQ5082 capsules 200 mg, NTQ5082 capsules 300 mg
- Volunteers
- 80 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Glomerulonephritis, IGA
ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN.
- Trial name
- NCT00378443
- Testing
- prednisone + Inhibace/Cozaar, Inhibace/Cozaar
- Sponsor
- Peking University
Primary IgA Nephropathy
A Trial to Evaluate the Long-term Safety and Tolerability of HRS-5965 in Patients With Primary IgA Nephropathy
This study aims to evaluate the long-term safety of HRS-5965 capsules in patients with primary IgA nephropathy, and also to assess its efficacy in reducing 24-hour urinary protein and delaying the decline in eGFR in these…
- Trial name
- NCT07582133
- Testing
- HRS-5965 Capsules
- Where
- China
- Volunteers
- 380 people
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Primary IgA Nephropathy
A Study of YKST02 in Participants With Primary IgA Nephropathy
The goal of this clinical trial is to evaluate the safety and tolerability of YKST02 and to explore its potential to treat adults with primary IgA nephropathy (IgAN).
- Trial name
- NCT07498673
- Testing
- YKST02
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Berger Disease, Bergers Disease
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to <18 years with primary immunoglobulin A nephropathy (IgAN).
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
- Trial name
- ADVANCE (NCT07498335)
- Testing
- Drug: Atrasentan
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Primary IgA Nephropathy
Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis in the world.There is to date no curative therapy for patients with IgAN.It is considered that dendritic cells, Toll-like receptor (TLR) 9 and…
- Trial name
- HCQIgAN (NCT02765594)
- Testing
- Hydroxychloroquine Sulfate, Valsartan
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Peking Union Medical College Hospital
IgA Nephropathy
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO® 16…
- Trial name
- NefXtend (NCT06712407)
- Testing
- TARPEYO®
- Where
- 38 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Calliditas Therapeutics AB
Primary IgA Nephropathy; Autoimmune Hepatitis
Relative Bioavailability Study of HR19042 in Healthy Subjects
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective： 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release…
- Trial name
- NCT06922305
- Testing
- HR19042 Capsule, Tarpeyo®, Budenofalk®
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Immunoglobulin A Nephropathy (IgAN)
A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN
The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.
- Trial name
- Verdant (NCT07773727)
- Testing
- ARGX-121
- Where
- 6 sites in United States, Japan
- Volunteers
- 120 people
- Sponsor
- argenx
Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis
Study of WAL0921 in Patients With Glomerular Kidney Diseases
This is an adaptive prospective, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of WAL0921 in subjects with glomerular kidney disease and…
- Conditions
- Diabetic Nephropathies, Primary Focal Segmental Glomerulosclerosis, Minimal Change Disease, Primary Immunoglobulin A Nephropathy
- Trial name
- NCT06466135
- Testing
- WAL0921
- Where
- 50 sites in United States, Australia and 5 more
- Volunteers
- 96 people
- Sponsor
- Walden Biosciences
Immunoglobulin a Nephropathy
A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy
This study will evaluate the efficacy and safety of HS-10390 in subjects with primary IgA nephropathy, and explore the optimal dose for the treatment.
- Trial name
- NCT06635772
- Testing
- HS-10390, Irbesartan
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hansoh BioMedical R&D Company
Immunoglobulin A (IgA) Nephropathy
PS-002 for the Treatment of IgA Nephropathy in Adults
The purpose of the study is to evaluate safety, tolerability, and preliminary effectiveness following administration of PS-002 in adults with primary Immunoglobulin A (IgA) nephropathy.
- Trial name
- NCT07182227
- Testing
- PS-002
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 32 people
- Sponsor
- Purespring Therapeutics Limited
IgA Nephropathy (IgAN)
IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy
Part 1 is a Single Ascending Dose (SAD) study, and Part 2 is a Multiple Ascending Dose (MAD) study
- Trial name
- NCT07886476
- Testing
- IBI3034, Telitacicept
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
IgA Glomerulonephritis
Early Application of Budesonide Enteric-coated Capsules in the Treatment of Primary IgA Nephropathy.
This multicenter, open-label, prospective single-arm study will enroll adults (≥18 y) with primary IgA nephropathy confirmed by renal biopsy within 2 weeks, eGFR ≥20 ml/min/1.73 m² and 0.5-3.5 g/d proteinuria, to receive early…
- Trial name
- NCT07585981
- Testing
- NEFECON
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
IgA Nephropathy (IgAN)
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
- Trial name
- NCT07390123
- Testing
- HSK39297
- Where
- 9 sites in China
- Volunteers
- 370 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
IgA Nephropathy, Lupus Nephritis
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
This is a Phase II trial assessing the safety and preliminary efficacy of daily APL-2 subcutaneous infusion administered for 16 weeks with a 6 month safety follow up, in patients with glomerulopathies
- Conditions
- IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis
- Trial name
- NCT03453619
- Testing
- APL-2
- Where
- 17 sites in United States
- Volunteers
- 21 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Glomerulonephritis, IGA, Probiotics
Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy
The goal of this clinical trial is to evaluate the efficacy and safety of probiotics combined with enteric-coated budesonide capsule in patients with IgA nephropathy on the basis of optimized RAS blockade therapy, and to explore…
- Conditions
- Glomerulonephritis, IGA, Probiotics, Budesonide
- Trial name
- NCT06528015
- Testing
- probiotics combined with enteric-coated budesonide capsule
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Gang Xu
IgA Nephropathy (IgAN)
SLN12140 in Adult Participants With IgA Nephropathy in China
This study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of…
- Trial name
- NCT07553494
- Testing
- SLN12140
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Linno Pharmaceuticals, Inc.
IgA Nephropathy (IgAN), Primary Membranous Nephropathy
Universal STAR-T Cell Injection in Autoimmune Kidney Diseases
This is an investigator initiated, single-arm, open-label, dose-escalation study to explore the preliminary efficacy, safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of the universal STAR-T…
- Trial name
- NCT07746453
- Testing
- Universal STAR-T Cell
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Guangdong Provincial People's Hospital